Exploring a new drug target for treating Toxoplasma gondii infections
Validation of the ubiquinone synthesis pathway of Toxoplasma gondii as a novel drug target
This study is looking at how the Toxoplasma gondii parasite makes a key substance that helps it survive, with the goal of finding new and better treatments for people, especially those with weakened immune systems, who are affected by toxoplasmosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10885996 on NIH RePORTER |
What this research studies
This research focuses on understanding the ubiquinone synthesis pathway in the Toxoplasma gondii parasite, which is known to cause serious infections, particularly in immunocompromised individuals. The study aims to validate this pathway as a potential target for new drug development, which could lead to more effective treatments for toxoplasmosis. By investigating how this parasite replicates and survives, researchers hope to identify novel therapeutic strategies that can overcome current treatment limitations. The approach involves detailed biochemical analysis and drug testing to assess the efficacy of targeting this pathway.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are immunocompromised due to conditions such as HIV/AIDS, cancer, or organ transplants, as well as pregnant women at risk of congenital toxoplasmosis.
Not a fit: Patients with asymptomatic Toxoplasma gondii infections or those who are not immunocompromised may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective treatments for toxoplasmosis, particularly benefiting immunocompromised patients.
How similar studies have performed: While the approach of targeting the ubiquinone synthesis pathway is innovative, similar strategies targeting mitochondrial functions in other parasites have shown promise in previous studies.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Moreno, Silvia N — University of Georgia
- Study coordinator: Moreno, Silvia N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.